Heart failure & cardiomyopathies
Rationale and Design of the TRIC-I-HF-DZHK24 (TRICuspid Intervention in Heart Failure) Trial
Study context
- Population
- Severe tricuspid regurgitation (TR) with manifest right-sided heart failure (HF) and increased risk for HF hospitalisation (HF hospitalizations (HFH) in previous year, cardio-renal syndrome or cardio-hepatic syndrome)≈360 planned
- Planned comparison
- Transcatheter tricuspid valve interventions (TTVI) + optimal medical therapy (OMT) vs OMT alone
Methodological detailsrationale and design, investigator-initiated, prospective, open-label, multicentre, strategy trial, 2:1 randomisation, hierarchical testing, Follow-up 3 years, 29 sites; mean of 176 tricuspid transcatheter edge-to-edge repair (T-TEER) patients in 4.5 years before activation, Safety outcome: TTVI complications, life-threatening bleeding and death
- Rationale and design
- Investigator-initiated
- Prospective
- Open-label
- Multicentre
- Strategy trial
- 2:1 randomisation
- Hierarchical testing
- Follow-up 3 years
- 29 sites; mean of 176 T-TEER patients in 4.5 years before activation
- Safety outcome: TTVI complications, life-threatening bleeding and death
No results yet. This paper sets out the design of a trial; its results are to come.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Rationale and Design of the TRIC-I-HF-DZHK24 (TRICuspid Intervention in Heart Failure) Trial. Eur J Heart Fail. Published 11 August 2025. doi:10.
Summarised from the published abstract; every number is checked against it